Meg Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. She is currently serving as Board Chair and is the Co-Founder of Target RWE. Meg has worked with multiple start-up companies while at Medgility, a consulting firm focused on strategy and business development of emerging companies. These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals. 

Prior to her work at Medgility, Meg was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and global development programs at all stages – from phase 1 to post patent expiry. Meg received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University.